Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide

HS Pandha, K Harrington, S Saini, J Lynn, M Peters, J Waxman

Summary
The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.

Keywords: octreotide, adrenal cortex, carcinoma

Introduction
Adrenal cortical carcinoma is a rare cause of Cushing's syndrome. At least half of all patients have metastatic disease at presentation. No adjuvant treatment is effective, and relapse is followed by a median survival of approximately three months. There is no effective cytotoxic drug or drug combination available for recurrent adrenal cortical carcinoma; 30–40% of patients will have a partial response to treatment, but the median survival is four months. The management of locally recurrent or metastatic tumour is therefore aimed at palliating symptoms secondary to hormonal hypersecretion, visceral pain, or bone pain. Agents such as mitotane and aminoglutethimide given to reduce hypercortisolism are relatively ineffective and are themselves toxic. There is a need for new treatments of this condition that are not toxic and which will palliate hypersecretory symptoms. For this reason we have explored the value of octreotide in adrenal cortical carcinoma.

Case report
A 46-year-old woman presented in May 1993 with weight gain, amenorrhoea, proximal myopathy, and severe acne. She had many of the clinical stigmata of Cushing's syndrome and a right-sided abdominal mass. Her initial 24-hour urinary free cortisol (UFCs) were greater than 3000 (normal range 0–270 nmol/24 h) and her morning plasma cortisol level was over 800 (normal range 200–700 nmol/l) with loss of diurnal variation, but without suppression of plasma or UFCs by high-dose dexamethasone. Adrenocorticotropic hormone (ACTH) levels were undetectable. There was marked hypokalaemic alkalosis and a raised serum testosterone level of 5.9 (normal range 0–3 nmol/l). Imaging investigations showed a large right-sided adrenal tumour without metastases.

A right adrenalectomy was performed and a large tumour weighing 585 g and measuring 12 × 12 × 7.5 cm was resected. Histology showed invasion of the pseudocapsule by an adrenal cortical carcinoma, with infiltration of a para-aortic lymph node and the inferior vena cava.

She made an excellent recovery from surgery with rapid resolution of all symptoms, although a short synacthen test four months later still showed some evidence of adrenal suppression. Serial 24-h UFCs were normal. Over the next six weeks her symptoms returned. Her 24-h UFCs were once again raised to over 3200 nmol, and restaging showed local recurrence, para-aortic lymphadenopathy, and pulmonary and liver metastases.

Over a period of three months she had symptomatic and radiological evidence of disease progression, uncontrolled by treatment with mitotane and aminoglutethimide which were both poorly tolerated. There was further disease progression despite metyrapone (500 mg, tid) and cisplatin 100 mg/m². At this point treatment was initiated with octreotide 300 µg subcutaneously tid in an attempt to palliate her secretory symptoms. A pre-treatment Octreoscan ([111]in-DTPA-D-Phe¹]octreotide, Mallinkrodt Diagnostica, Petten, Holland) was negative for somatostatin receptors and showed reduced uptake in the metastases. Her symptoms improved rapidly with octreotide with an accompanying reduction in UFCs but not serum levels of testosterone or dihydroepiandrosterone sulphate (figure). The improvement was sustained, enabling the patient to return to her home overseas.

Comment
Octreotide is effective at controlling endocrine hypersecretion and hormone-induced symptoms associated with a variety of functional endocrine tumours. In view of the lack of therapeutic options for adrenal cortical carcinoma and the broad spectrum of inhibitory endocrine effects of somatostatin analogues, octreotide was successfully applied as treat-
ment for refractory Cushing's syndrome secondary to a secretory adrenal cortical carcinoma.

The therapeutic effect of somatostatin analogues in Cushing's syndrome is not established. Octreotide may interfere directly with adrenal steroidogenesis, but most of the available data suggest an inhibitory effect on ACTH secretion. Receptors for somatostatin have been demonstrated in the zona glomerulosa and somatostatin has been shown to inhibit aldosterone secretion. A marked decrease of plasma cortisol levels with infusional somatostatin was observed by Aynsley-Green et al in an evaluation of the influence of this peptide on insulin secretion. Octreotide has also been shown to reduce UFCs in patients with ACTH-dependent Cushing's syndrome, but the primary site of action of somatostatin could not be inferred from any of these studies.

In our patient, despite the negative Octreoscan, there was a rapid symptomatic and biochemical improvement in response to octreotide. The mechanism for this is unknown.

The response to octreotide in ACTH-independent adrenal cell carcinoma demonstrated by the serial measurement of UFCs has not previously been reported. In view of the limited efficacy of current agents in adrenal cortical carcinoma, a trial of octreotide to control secretory symptoms in patients with this condition would seem reasonable.

We thank Dr J Lambert and Dr R Scott for referring the patient.